Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: Suggestions from bench to bedside

Cancer and Metastasis Reviews

Volumn 33, Issue 1, 2014, Pages 321-331

  Santoni, Matteo ^a   Santini, Daniele ^b   Massari, Francesco ^c   Conti, Alessandro ^a   Iacovelli, Roberto ^d   Burattini, Luciano ^a   Tortora, Giampaolo ^c   Falconi, Massimo ^a   Montironi, Rodolfo ^e   Cascinu, Stefano ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e OSPEDALI RIUNITI   (Italy)

Author keywords

Metastatic sites; Patient outcome; Primary tumor; Renal cell carcinoma; Targeted therapy; Tumor heterogeneity

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; INTERLEUKIN 2; PEGINTERFERON ALPHA2B; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VON HIPPEL LINDAU PROTEIN; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT;

ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE DESTRUCTION; BONE LESION; BONE METASTASIS; BONE REMODELING; BRAIN; BRAIN METASTASIS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHROMOSOME ABERRATION; COUGHING; DISTANT METASTASIS; DRUG EFFICACY; GENE EXPRESSION; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIVER METASTASIS; NEPHRECTOMY; NONHUMAN; OSTEOLYSIS; PRIMARY TUMOR; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOMATIC MUTATION; STEREOTACTIC RADIOSURGERY; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE; TUMOR GENE; TUMOR VOLUME; WEAKNESS; CARCINOMA, RENAL CELL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; KIDNEY NEOPLASMS; METASTASIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; RADIATION RESPONSE; RADIOTHERAPY;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; RADIOTHERAPY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84899921035     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9453-5     Document Type: Article

References (82)

1. Ljungberg, B., Cowan, N. C., Hanbury, D. C., Hora, M., Kuczyk, M. A., Merseburger, A. S., et al. (2010). EAU guidelines on renal cell carcinoma: the 2010 update. European Urology, 58, 398-406.
2. MacLennan, G. T., & Bostwick, D. G. (1995). Microvessel density in renal cell carcinoma: lack of prognostic significance. Urology, 46, 27-30.
3. Folkman, J. (1992). The role of angiogenesis in tumor growth. Semininars in Cancer Biology, 3, 65-71.
4. Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., et al. (2007). Sorafenib in advanced clear-cell renal-cell carcinoma. The New England Journal of Medicine, 356, 125-134.
5. Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, D., Bukowski, R. M., Rixe, O., et al. (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. The New England Journal of Medicine, 356, 115-124.
6. Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., et al. (2007). Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. The New England Journal of Medicine, 356, 2271-2281.
7. Escudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., et al. (2007). Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized, double-blind phase III trial. The Lancet, 370, 2103-2111.
8. Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., et al. (2008). Efficacy of everolimus in advanced renal cell carcinoma: a double-blind randomised placebo-controlled phase III trial. The Lancet, 372, 449-456.
9. Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Ou, S. S., et al. (2008). Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. The Journal of Clinical Oncology, 26, 5422-5428.
10. Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., et al. (2010). Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. The Journal of Clinical Oncology, 28, 1061-1068.
11. Rini, B. I., Escudier, B., Tomczack, P., Kaprin, A., Szczylik, C., Hutson, T. E., et al. (2011). Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. The Lancet, 378, 1931-1939.
12. Iacovelli, R., Alesini, D., Palazzo, A., Trenta, P., Santoni, M., De Marchis, L., et al. (2013). Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials. Cancer Treatment Reviews. doi: 10.1016/j.ctrv.2013.09.003.
13. Flanigan, R. C., Salmon, S. E., Blumenstein, B. A., Bearman, S. I., Roy, V., McGrath, P. C., et al. (2001). Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. The New England Journal of Medicine, 345, 1655-1659.
14. McKay, R. R., Kroeger, N., Xie, W., Lee, J. L., Knox, J. J., Bjarnason, G. A., et al. (2013). Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. European Urology. doi: 10.1016/j.eururo.2013.08.012.
15. O'Dea, M. J., Zincke, H., Utz, D. C., & Bernatz, P. E. (1978). The treatment of renal cell carcinoma with solitary metastasis. The Journal of Urology, 120, 540-542.
16. Kroeger, N., Choueiri, T. K., Lee, J. L., Bjarnason, G. A., Knox, J. J., Mackenzie, M. J., et al. (2013). Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. European Urology. doi: 10.1016/j.eururo.2013.07.031.
17. Amin, C., Wallen, E., Pruthi, R. S., Calvo, B. F., Godley, P. A., & Rathmell, W. K. (2008). Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology, 2008(72), 864-868.
18. Shuch, B., Riggs, S. B., LaRochelle, J. C., Kabbinavar, F. F., Avakian, R., Pantuck, A. J., et al. (2008). Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. The British Journal of Urology International, 102, 692-696.
19. Thomas, A. A., Rini, B. I., Lane, B. R., Garcia, J., Dreicer, R., Klein, E. A., et al. (2009). Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. The Journal of Urology, 181, 518-523.
20. van der Veldt, A. A., Meijerink, M. R., van den Eertwegh, A. J., Bex, A., de Gast, G., Haanen, J. B., et al. (2008). Sunitinib for treatment of advanced renal cell cancer: primary tumor response. Clinical Cancer Research, 14, 2431-2436.
21. Abel, E. J., Culp, S. H., Tannir, N. M., Matin, S. F., Tamboli, P., Jonasch, E., et al. (2011). Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. European Urology, 59, 10-15.
22. Zigeuner, R., Ratschek, M., Rehak, P., Schips, L., & Langner, C. (2004). Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. Urology, 63, 651-655.
23. Aziz, S. A., Sznol, J., Adeniran, A., Colberg, J. W., Camp, R. L., & Kluger, H. M. (2013). Vascularity of primary and metastatic renal cell carcinoma specimens. Journal of Translational Medicine, 11, 15.
24. Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., et al. (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. The New England Journal of Medicine, 366, 883-892.
25. Xu, X., Hou, Y., Yin, X., Bao, L., Tang, A., Song, L., et al. (2012). Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell, 148, 886-895.
26. Aziz, S. A., Sznol, J. A., Adeniran, A., Parisi, F., Kluger, Y., Camp, R. L., et al. (2013). Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors. BMC Clinical Pathology, 13, 3.
27. Abou Youssif, T., Fahmy, M. A., Koumakpayi, I. H., Ayala, F., Al Marzooqi, S., Chen, G., et al. (2011). The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer, 117, 290-300.
28. Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., et al. (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer, 45, 228-247.
29. Nishino, M., Jagannathan, J. P., Krajewski, K. M., O'Regan, K., Hatabu, H., Shapiro, G., et al. (2012). Personalized tumor response assessment in the era of molecular medicine: cancer specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR. American Journal of Roentgenology, 198, 737-745.
30. Baccala, A., Hedfepeth, R., Kaouk, J., Magi-Galluzzi, C., Gilligan, T., & Fergany, A. (2007). Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib. International Journal of Urology, 14, 1095-1097.
31. Han, K. S., Jung, D. C., Choi, H. J., Jeong, M. S., Cho, K. S., Joung, J. Y., et al. (2010). Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy. Cancer, 116, 2332-2342.
32. Schwartz, L. H., Mazumdar, M., Wang, L., Smith, A., Marion, S., Panicek, D. M., et al. (2003). Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials. Cancer, 98, 1611-1619.
33. Derwinger, K., Kodeda, K., & Gerjy, R. (2010). Age aspects of demography, pathology and survival assessment in colorectal cancer. Anticancer Research, 30, 5227-5231.
34. Beck, S. D., Patel, M. I., Snyder, M. E., Kattan, M. W., Motzer, R. J., Reuter, V. E., et al. (2004). Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Annals of Surgical Oncology, 11, 71-77.
35. Renshaw, A. A., & Richie, J. P. (1999). Subtypes of renal cell carcinoma: different onset and sites of metastatic disease. Am Journal of Clinical Patholology, 111, 539-543.
36. Snow, R. M., & Schellhammer, P. F. (1982). Spontaneous regression of metastatic renal cell carcinoma. Urology, 20, 177-181.
37. López-Lago, M. A., Posner, S., Thodima, V. J., Molina, A. M., Motzer, R. J., & Chaganti, R. S. (2012). Neutrophil chemokines secreted by tumor cells mount a lung antimetastatic response during renal cell carcinoma progression. Oncogene. doi: 10.1038/onc.2012.201.
38. Merimsky, O., Gez, E., Weitzen, R., Nehushtan, H., Rubinov, R., Hayat, H., et al. (2004). Targeting pulmonary metastases of renal cell carcinoma by inhalation of interleukin-2. Annals of Oncology, 15, 610-612.
39. Bianchi, M., Sun, M., Jeldres, C., Shariat, S. F., Trinh, Q. D., Briganti, A., et al. (2012). Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Annals of Oncology, 23, 973-980.
40. Fidler, I. J. (2003). The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nature Reviews Cancer, 3, 453-458.
41. Woodward, E., Jagdev, S., McParland, L., Clark, K., Gregory, W., Newsham, A., et al. (2001). Skeletal complications and survival in renal cancer patients with bone metastases. Bone, 48, 160-166.
42. Kominsky, S. L., Doucet, M., Brady, K., & Weber, K. L. (2007). TGF-beta promotes the establishment of renal cell carcinoma bone metastasis. Journal of Bone and Mineral Research, 22, 37-44.
43. Weber, K., Doucet, M., & Kominsky, S. (2007). Renal cell carcinoma bone metastasis-elucidating the molecular targets. Cancer and Metastasis Reviews, 26, 691-704.
44. Beuselinck, B., Oudard, S., Rixe, O., Wolter, P., Blesius, A., Ayllon, J., et al. (2011). Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Annals of Oncology, 22, 794-800.
45. Choueiri, T., Garcia, J. A., Elson, P., Khasawneh, M., Usman, S., Golshayan, A. R., et al. (2007). Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer, 110, 543-550.
46. Riechelmann, R. P., Chin, S., Wang, L., Tannock, I. F., Berthold, D. R., Moore, M. J., et al. (2008). Sorafenib for metastatic renal cancer: the Princess Margaret experience. American Journal of Clinical Oncology, 31, 182-187.
47. Santini, D., Procopio, G., Porta, C., Ibrahim, T., Barni, S., Mazzara, C., et al. (2013). Natural history of malignant bone disease in renal cancer: final results of an Italian Bone Metastasis Survey. PLOSONE (in press).
48. Zolnierek, J., Nurzynski, P., Langiewicz, P., Oborska, S., Waśko-Grabowska, A., Kuszatal, E., et al. (2010). Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases. Journal of Cancer Research and Clinical Oncology, 136, 371-378.
49. Maita, S., Yuasa, T., Tsuchiya, N., Mitobe, Y., Narita, S., Horikawa, Y., et al. (2012). Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function. International Journal of Cancer, 130, 677-684.
50. Keizman, D., Ish-Shalom, M., Pili, R., Hammers, H., Eisenberger, M. A., Sinibaldi, V., et al. (2012). Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. European Journal of Cancer, 48, 1031-1037.
51. Beuselinck, B., Wolter, P., Karadimou, A., Elaidi, R., Dumez, H., Rogiers, A., et al. (2012). Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. British Journal of Cancer, 107, 1665-1671.
52. Kneissel, M., Luong-Nguyen, N. H., Baptist, M., Cortesi, R., Zumstein-Mecker, S., Kossida, S., et al. (2004). Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. Bone, 35, 1144-1156.
53. Sugatani, T., & Hruska, K. A. (2005). Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. The Journal of Biological Chemistry, 280, 3583-3589.
54. Hussein, O., Tiedemann, K., Murshed, M., & Komarova, S. V. (2012). Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastases. Cancer Letters, 314, 176-184.
55. Okui, T., Shimo, T., Fukazawa, T., Kurio, N., Hassan, N. M., Honami, T., et al. (2010). Antitumor effect of temsirolimus against oral squamous cell carcinoma associated with bone destruction. Molecular Cancer Therapeutics, 9, 2960-2969.
56. Kassabinn, A., Stein, J., Jabbour, N., Parsa, K., Skinner, D., Parekh, D., et al. (2000). Renal cell carcinoma metastatic to the pancreas: a single-institution series and review of the literature. Adult Urology, 56(211-215), 2000.
57. Shah, S., & Mortele, K. J. (2007). Uncommon solid pancreatic neoplasms: ultrasound, computed tomography, magnetic resonance imaging features. Seminars in Ultrasound, CT, and MR, 28, 357-370.
58. Ballarin, R., Spaggiari, M., Cautero, N., De Ruvo, N., Montalti, R., Longo, C., et al. (2011). Pancreatic metastases from renal cell carcinoma: the state of the art. World Journal of Gastroenterology, 17, 4747-4756.
59. Wente, M. N., Kleeff, J., Esposito, I., Hartel, M., Müller, M. W., Fröhlich, B. E., et al. (2005). Renal cancer cell metastasis into the pancreas. Pancreas, 30, 218-222.
60. Medioni, J., Choueiri, T. K., Zinzindohouè, F., Cho, D., Fournier, L., Oudard, S., et al. (2009). Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: a retrospective analysis. The Journal of Urology, 181, 2470-2475.
61. Grassi, P., Verzoni, E., Mariani, L., De Braud, F., Coppa, J., Mazzaferro, V., et al. (2013). Prognostic role of pancreatic metastases from renal cell carcinoma: results from an Italian Center. Clinical Genitourinary Cancer. doi: 10.1016/j.clgc.2013.04.022.
62. Sheehan, J. P., Sun, M. H., Kondziolka, D., Flickinger, J., & Lunsford, L. D. (2003). Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control. Journal of Neurosurgery, 98, 342-349.
63. Delattre, J. Y., Krol, G., Thaler, H. T., & Posner, J. B. (1988). Distribution of brain metastases. Archives of Neurology, 45, 741-744.
64. Wronski, M., Maor, M. H., Davis, B. J., Sawaya, R., & Levin, V. A. (1997). External radiation of brain metastases from renal carcinoma: a retrospective study of 119 patients from the M. D. Anderson Cancer Center. International Journal of Radiation Oncology, Biology, Physics, 37, 753-759.
65. Cannady, S. B., Cavanaugh, K. A., Lee, S. Y., Bukowski, R. M., Olencki, T. E., Stevens, G. H., et al. (2004). Results of whole brain radiotherapy and recursive partitioning analysis in patients with brain metastases from renal cell carcinoma: a retrospective study. International Journal of Radiation Oncology, Biology, Physics, 58, 253-258.
66. Culine, S., Bekradda, M., Kramar, A., Rey, A., Escudier, B., & Droz, J. P. (1998). Prognostic factors for survival in patients with brain metastases from renal cell carcinoma. Cancer, 83, 2548-2553.
67. Gore, M. E., Hariharan, S., Porta, C., Bracarda, S., Hawkins, R., Bjarnason, G. A., et al. (2011). Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer, 117, 501-509.
68. Stadler, W. M., Figlin, R. A., McDermott, D. F., Dutcher, J. P., Knox, J. J., Miller, W. H., Jr., et al. (2010). Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer, 116, 1272-1280.
69. Vanhuyse, M., Penel, N., Caty, A., Fumagalli, I., Alt, M., Zini, L., et al. (2012). Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma? Bulletin du Cancer, 99, 100-106.
70. Verma, J., Jonasch, E., Allen, P., Tannir, N., & Mahajan, A. (2011). Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. Cancer, 117, 4958-4965.
71. Verma, J., Jonasch, E., Allen, P. K., Weinberg, J. S., Tannir, N., Chang, E. L., et al. (2012). The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma. American Journal of Clinical Oncology, 36(6), 620-624.
72. Dudek, A. Z., Raza, A., Chi, M., Singhal, M., Oberoi, R., Mittapalli, R. K., et al. (2013). Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors. Clinical Genitourinary Cancer, 11, 155-160.
73. Cochran, D. C., Chan, M. D., Aklilu, M., Lovato, J. F., Alphonse, N. K., Bourland, J. D., et al. (2012). The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery. Journal of Neurosurgery, 116, 978-983.
74. Fukata, S., Inoue, K., Kamada, M., Kawada, C., Furihata, M., Ohtsuki, Y., et al. (2005). Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organ-specific metastasis of renal cell carcinoma. Cancer, 103, 931-942.
75. Van der Veldt, A. A. M., Meijerink, M. R., Van der Eertwegh, A. J. M., Haanen, J. B., Boven, E., et al. (2010). Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. British Journal of Cancer, 102, 803-809.
76. Schmidt, N., Hess, V., Zumbrunn, T., Rothermundt, C., Bongartz, G., & Potthast, S. (2013). Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies. European Radiology, 23, 632-639.
77. Smith, A. D., Leiber, M. L., & Shah, S. N. (2010). Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR. American Journal of Roentgenology, 194, 157-165.
78. Thiam, R., Fournier, L. S., Trinquart, L., Medioni, J., Chatellier, G., Balvay, D., et al. (2010). Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Annals of Oncology, 21, 936-941.
79. Krajewski, K. M., Guo, M., Van der Abbeele, A. D., Yap, J., Ramaiya, N., Jagannathan, J., et al. (2011). Comparison of four early post therapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. European Urology, 59, 856-862.
80. Oudard, S., Thiam, R., Fournier, L. S., Medioni, J., Lamuraglia, M., Scotte, F., et al. (2012). Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: Analysis of response and progression-free survival in the RECORD-1 study. European Journal of Cancer, 48, 1512-1528.
81. Smith, A. D., Shah, S. N., Rini, B. I., Lieber, M. L., Remer, E. M., et al. (2010). Morphology, attenuation, size and structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR. American Journal of Roentgenology, 194, 1470-1478.
82. Hittinger, M., Staehler, M., Schramm, N., Ubleis, C., Becker, C., Reiser, M., et al. (2012). Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy. Urologic Oncology, 30, 695-703.